Home Endocrinology & Hormones Androgen Receptor inhibitor N-desMethyl EnzalutaMide

research use only

N-desMethyl EnzalutaMide Androgen Receptor inhibitor

Cat.No.S3542

N-desMethyl EnzalutaMide (N-desmethyl MDV 3100) is the active metabolite of Enzalutamide, which is an oral androgen receptor inhibitor for treatment of castration-resistant prostate cancer.
N-desMethyl EnzalutaMide Androgen Receptor inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 450.41

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: S354201 DMSO]90 mg/mL]false]Ethanol]5 mg/mL]false]Water]Insoluble]false Purity: 99.96%
99.96

Chemical Information, Storage & Stability

Molecular Weight 450.41 Formula

C20H14F4N4O2S

 Storage (From the date of receipt) 3 years -20°C powder
CAS No. 1242137-16-1 -- Storage of Stock Solutions

Synonyms N-desmethyl MDV 3100 Smiles CC1(C)N(C(=S)N(C1=O)C2=CC(=C(C=C2)C#N)C(F)(F)F)C3=CC(=C(C=C3)C(N)=O)F

Solubility

In vitro
Batch:

DMSO : 90 mg/mL (199.81 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 5 mg/mL

Water : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03016312 Completed
Prostatic Neoplasms Castration-Resistant
Hoffmann-La Roche
 January 10 2017 Phase 3
NCT02929576 Withdrawn
Breast Cancer
Pfizer|Astellas Pharma Inc|Medivation Inc.
 September 2016 Phase 3
NCT02528643 Completed
Advanced Hepatocellular Carcinoma
Astellas Pharma Global Development Inc.|Pfizer|Astellas Pharma Inc
 November 9 2015 Phase 2
NCT02215096 Completed
Neoplasms
GlaxoSmithKline
 November 13 2014 Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map